Begin main content

Reports

We found 6384 result(s)

halobetasol propionate and tazarotene (TBC)

Last Updated: May 31, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: halobetasol propionate and tazarotene
Indications: Psoriasis, moderate to severe plaque

  • Brand Name: TBC
  • Manufacturer: Bausch Health, Canada Inc.
  • Project Number: SR0600-000
  • Project Status: Withdrawn
  • Submission Type: New

insulin glargine (Semglee)

Last Updated: May 31, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: insulin glargine
Indications: Diabetes mellitus, Type 1 & 2

  • Brand Name: Semglee
  • Manufacturer: BGP PHARMA ULC
  • Project Number: SE0589-000
  • Project Status: Withdrawn
  • Submission Type: New

pegfilgrastim (Fulphila )

Last Updated: May 31, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: pegfilgrastim
Indications: Febrile neutropenia in non-myeloid malignancies

  • Brand Name: Fulphila
  • Manufacturer: BGP PHARMA ULC
  • Project Number: SE0588-000
  • Project Status: Complete
  • Submission Type: New

CADTH pan-Canadian Oncology Drug Review

Published on: June 17, 2019
Result type: General Content

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process. The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces ...